Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

72.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - A Promising Affordable Growth Stock
CORCEPT THERAPEUTICS (NASDAQ:CORT) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks. 
Via Chartmill
1 Cash-Producing Stock Worth Your Attention and 2 to Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Here's How Much $100 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth Today
Via Benzinga
3 Russell 2000 Stocks in Hot Water
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Earnings Scheduled For May 5, 2025
Via Benzinga
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a candidate for growth investors. High revenue growth, profitability, and a debt-free... 
Via Chartmill
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
From Corcept Therapeutics Incorporated
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3. 
Via Benzinga
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
From Corcept Therapeutics Incorporated
Via Business Wire
2 Profitable Stocks to Target This Week and 1 to Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
1 Growth Stock with All-Star Potential and 2 to Avoid
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID... 
Via StockStory
Topics Artificial Intelligence
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
CORCEPT THERAPEUTICS (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High revenue growth, profitability, and a debt-free balance sheet support... 
Via Chartmill
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s... 
Via StockStory
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
Via Benzinga
Looking for growth without the hefty price tag? Consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
How Do Investors Really Feel About Corcept Therapeutics?
Via Benzinga
Will CORCEPT THERAPEUTICS INC (NASDAQ:CORT) breakout?
Exploring CORCEPT THERAPEUTICS INC's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:CORT Could Be on the Verge of a Breakout. 
Via Chartmill
1 Small-Cap Stock Worth Your Attention and 2 to Question
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars
The pharma company saw a surge in retail sentiment following its Q1 update, which reaffirmed its 2025 revenue guidance of $900 million to $950 million. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s... 
Via StockStory
Topics Artificial Intelligence
Top movers in Monday's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
From Corcept Therapeutics
Via Business Wire
Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings tomorrow after the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.